2. (Amended) The pharmaceutical composition according to claim 1, wherein the pharmaceutically tolerable ester of loteprednol is loteprednol etabonate.

3. (Amended) The pharmaceutical composition according to claim 1, wherein the β_2 adrenoceptor agonist is selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol and their pharmaceutically tolerable salts.

4. (Amended) The pharmaceutical composition according to claim 1, which comprises (i) loteprednol and (ii) formoterol.

5. (Amended) The pharmaceutical composition according to claim 1, which comprises (i) loteprednol and (ii) salmeterol.

6. (Amended) The pharmaceutical composition according to claim 1, which comprises (i) loteprednol and (ii) reproterol.

7. (Amended) A method for the treatment of allergies and/or airway disorders, comprising administering to a patient in need of such treatment an efficacious amount of (i) loteprednol and (ii) at least one β_2 adrenoceptor agonist, if appropriate together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

8. (Amended) A process for the preparation of a pharmaceutical composition for the treatment of allergies and/or airway disorders, comprising an effective amount of the active compound loteprednol and at least one β_2 adrenoceptor agonist, wherein loteprednol and the β_2 adrenoceptor agonist or the β_2 adrenoceptor agonists are mixed individually or together, if appropriate together with customary excipients or vehicles, and the mixture thus obtained is converted into suitable administration forms.